AVERT Trial
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
AVERT Trial On the Web |
|
American Roentgen Ray Society Images of AVERT Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To compare the outcome of aggressive lipid lowering to that of angioplasty in stable coronary artery disease patients, relatively normal left ventricular function, asymptomatic or mild-to-moderate angina, and a serum level of LDL-C of at least 115 mg/dL who were referred for percutaneous revascularization.
Methods
Atorvastatin versus Revascularization Treatment (AVERT) trial was a randomized comparative study that enrolled 341 patients with stable CAD. All the patients were randomly assigned to treatment with either atorvastatin 80 mg per day or percutaneous revascularization procedure (angioplasty) followed by usual care. The follow-up period was 18 months.
Results
At the end of follow-up period atorvastatin was associated with 36% lower incidence of ischemic events compared to angioplasty. Also, patients who received atorvastatin had a significantly longer time to the first ischemic event.
Conclusion
Aggressive lipid lowering therapy with atorvastatin is at least as effective as angioplasty in reducing the incidence of ischemic events in low-risk patients with stable CAD.[1][2]
References
- ↑ Pitt B, Waters D, Brown WV; et al. (1999). "Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators". The New England Journal of Medicine. 341 (2): 70–6. doi:10.1056/NEJM199907083410202. PMID 10395630. Unknown parameter
|month=ignored (help) - ↑ Waters DD (2000). "Medical therapy versus revascularization: the atorvastatin versus revascularization treatment AVERT trial". The Canadian Journal of Cardiology. 16 Suppl A: 11A–3A. PMID 10653925. Unknown parameter
|month=ignored (help)